Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BFKB8488A versus placebo in adults with non-alcoholic steatohepatitis
2019-001897-27Phase 2Completed
- Sponsor
- Genentech
- Start
- Oct 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing BFKB8488A with Placebo (2 arms). Primary endpoint: Resolution of NASH without worsening of fibrosis. Started Oct 2019; status: completed.
02
Drugs
fazpilodemab
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2019-001897-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001897-27.